
Expert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.

Your AI-Trained Oncology Knowledge Connection!


Expert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.

A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.

Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.

Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.

Published: March 30th 2022 | Updated:

Published: August 10th 2021 | Updated:

Published: July 13th 2021 | Updated:

Published: April 27th 2022 | Updated:

Published: March 30th 2022 | Updated:

Published: April 20th 2022 | Updated: